OOIR: Observatory of International Research

Papers

(The median citation count of Melanoma Research is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	31
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study	30
Rurality as a predictor of melanoma stage and treatment in Indiana: a retrospective cohort study	23
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	22
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	19
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	18
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	18
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	17
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	16
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	15
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	15
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	14
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	14
Brain metastases during follow-up of patients with resected cutaneous melanoma	12
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	12
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	12
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	11
Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	11
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	10
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	10
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	10
Immunotherapy-induced granulomatous reaction in patients with melanoma	10
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	9
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	9
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	9

Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	9
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Ultraviolet A radiation exposure and melanoma: a review	8
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	8
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	8
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	8
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	8
Multiple melanoma, ichthyosis, and juvenile cataracts in a patient with a germline mutation in CDKN2A: pure coincidence or related association?	8
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	8
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	7
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	7
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	7
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	7
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	6
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors	6
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	6
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	5
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	5
Trends of adverse event reports associated with BRAF and MEK inhibitors and combinations: a retrospective disproportionality analysis using the FDA adverse event reporting system database from 2012 to	5
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	5
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	5
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	5
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	5
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials	5
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	5
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	5
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	5
Simultaneous melanomas in the setting of multiple primary melanomas	5
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	5
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	5
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	5
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	5
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	5
Melanoma risk during immunomodulating treatment	5
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	5
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	5
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	5
Molecular profiling of primary uveal melanoma: results of a Polish cohort	4
Combined PDE4+MEK inhibition shows antiproliferative effects in NRAS Q61 mutated melanoma preclinical models	4
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
Upregulation of SFTPC gene expression is associated with disease progression and worse survival outcomes in human skin melanomas	4
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	4
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	4
Neonatal cutaneous melanoma with cutaneous metastasis: a case report and review of literature	3
First-time office visit for suspicious skin lesion evaluation as a predictor of high-risk melanoma	3
A deep learning-based radiomics model for noninvasive diagnosis of melanoma	3
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis	3

Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	3
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	3
High-resolution RNA-sequencing reveals TRIM33::CSDE1 gene fusion in metastasizing vulvar melanoma	3
Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma	3
ATF3 regulates CDC42 transcription and influences cytoskeleton remodeling, thus inhibiting the proliferation, migration and invasion of malignant skin melanoma cells	3
Uveal melanoma metastatic at initial diagnosis: a case series	3
Noncontrast-enhanced 3-Tesla MRI using surface coil as a complementary test for assessment of distribution and depth of locoregional cutaneous metastases of malignant melanoma	3
Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice	3
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors	3
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	3
Melanoma and pregnant women: a systematic review and meta-analysis	3
Breaking barriers: epithelial–mesenchymal transition role in melanoma invasion and resistance	3
Efficacy of local ablative therapies in patients with solid tumors treated with immune checkpoint inhibitors and oligoprogression: a single-center analysis	3
Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging	3
Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA)	3
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy	3
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)	3
Nomograms versus artificial intelligence platforms: which one can better predict sentinel node positivity in melanoma patients?	3
Survival in adult patients with BRAFV600 mutation-positive advanced melanoma: a noninterventional ambispective study of patients with cobimetinib combined with vemurafenib during the French early acce	3
Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas	3
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	3
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	3
Exploring the role of epigenetic alterations and non-coding RNAs in melanoma pathogenesis and therapeutic strategies	3
Polymorphisms in toll-like receptor 3 and 4 genes as prognostic and outcome biomarkers in melanoma patients	3
Psychosocial wellbeing in people with melanoma in-situ: a systematic review	3
Retrospective comparison of a weight-based dose every 2 weeks with a fixed dose every month: a real-life analysis of nivolumab in the treatment of advanced melanoma	3
Direct early growth response-1 knockdown decreases melanoma viability independent of mitogen-activated extracellular signal-related kinase inhibition	3
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	2
Immunohistochemistry assessment of tissue neutrophil-to-lymphocyte ratio predicts outcomes in melanoma patients treated with anti-programmed cell death 1 therapy	2
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma	2
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization	2
Rate of response to immune checkpoint inhibitor therapy in patients with conjunctival melanoma	2
Prognostic significance of tumor budding in melanoma	2
Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience	2
Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene	2
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab	2
Female melanoma and estrogen receptors expression: an immunohistochemical pilot study	2
Cardiovascular disease and malignant melanoma	2
Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study	2
pSTAT5 is associated with improved survival in patients with thick or ulcerated primary cutaneous melanoma	2
Diagnosis and management of concurrent metastatic melanoma and chronic myelomonocytic leukemia	2
Clinical features of vulvar and vaginal malignant melanomas and the effects of immune checkpoint inhibitors in Japanese patients: a single-center, retrospective cohort study	2
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma	2
Epidemiologic characteristics of de novo versus nevus-associated melanoma	2
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic	2
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma	2
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma	2
Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results	2
Development and validation of prognostic nomogram in pediatric melanoma: a population-based study	2
Melanoma risk prediction based on a polygenic risk score and clinical risk factors	2
New technique for in-continuity axillary and supraclavicular lymphadenectomy for advanced metastatic melanoma using intraoperative image guidance: a case report	2
Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients	2
Regorafenib in patients with pretreated advanced melanoma: a single-center case series	2
Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma	2
Pregnancy-associated melanoma: characteristics and outcomes from 2002 to 2020	2
Clinical performance indicators for monitoring the management of cutaneous melanoma: a population-based perspective	2
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis	2
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series	2
Description of supportive care and feasibility of physical exercise program to improve quality of life in advanced melanoma patients	2
The effect of COVID-19 on early melanoma detection	2
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome	2
Vitiligo-like hypopigmentation secondary to adjuvant checkpoint inhibitor therapy in patients with resectable stage III melanoma: a cohort from two tertiary hospitals	2
Preoperative assessment of cutaneous melanoma thickness by multispectral dermoscopy	2
The association between dermatologist density and melanoma prognosis using melanoma mortality-incidence ratio	2
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients	2
The role of artificial intelligence and convolutional neural networks in the management of melanoma: a clinical, pathological, and radiological perspective	2
Talimogene laherparepvec monotherapy for head and neck melanoma patients	2
Underreporting of acral lentiginous melanoma in studies informing American Joint Committee on Cancer Staging System Guidelines: a review of 150 cited studies	2
Expect the unexpected: a saying to bear in mind	2
Retro- and prospective histologic and immunohistochemical analysis of safety margins following complete excision of less than 1 mm melanomas	2